Trial Profile
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms STaMINA
- 31 May 2020 Primary endpoint (Compare the PFS as a time to event analysis from randomization on the BMT CTN 0702 protocol between the three randomized treatment arms as a pairwise comparison.) has been met.
- 31 May 2020 Results assessing 6 year follow up for STaMINA and the results of Len discontinuation beyond 3 years, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 03 Sep 2019 Status changed from active, no longer recruiting to completed.